Pharmaceutical patent strategy is often treated like a filing exercise—until the courtroom, the PTAB, or the payor negotiation arrives and turns “paper value” into real-world economics.
The hard truth: in drug IP, you don’t just decide whether a patent…

The clock is already ticking. Most “market access” teams are just late.
In pharma, timing isn’t a slogan—it’s a competitive advantage. If you’re a commercial market access vendor selling into the life sciences ecosystem, the biggest mistake you can mak…

Before You Launch: The Freedom-to-Operate Checklist That Can Save Your Next Product
Launching a pharma product is a race against time, capital, and competition. But there’s another race—one that can quietly decide whether your launch becomes a breakthr…

Pharma procurement teams spend a lot of time on the “obvious” risks: contract terms, supply continuity, pricing mechanics, and manufacturing capacity. But there’s a quieter, higher-impact risk that many buyers still treat like an afterthought—Paragraph…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or in-house counsel, you’ve probably heard the same comforting story: “Patent protection lasts X years.” In Asia…

Drug patent expiry dates aren’t just legal milestones—they’re commercial inflection points. And most life sciences teams treat them like back-office trivia instead of a revenue roadmap.
Here’s the agitation: when a patent cliff approaches, everyone scr…

Sell the line before the patent breaks. That’s the uncomfortable truth many pharma suppliers learn too late—right when the litigation clock runs out and the commercial clock starts. In solid dose manufacturing, timing isn’t a “nice-to-have.” It’s the d…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

The Smarter Monopoly? Orphan Drug Exclusivity vs. Standard Drug Patents
There’s a quiet but consequential shift happening in how the U.S. rewards innovation in pharmaceuticals—and it’s not just a policy debate. It’s a market design question.
On one sid…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
The cliff is coming—and in biologics, it arrives faster than most commercial teams expect.
Loss of exclusivity (LOE) for biologics doesn’t…